Owing to its important role in cancer progression and in limiting the efficacy of anti-cancer therapies, blocking IGF1R combined with other inhibitors is under clinical development in various cancer types, including melanoma36, lung37, breast38, and prostate cancers39. This evidence concerns the gene IGF1R and cancer.